Image_3_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

Image_6_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

Image_1_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

DataSheet_1_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.xls by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

DataSheet_2_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.xls by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

Image_5_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

Image_4_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

Table_1_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.xls by Diogo F. T. Veiga (12282320)

“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”

Bioreductively Activatable Prodrug Conjugates of Combretastatin A‑1 and Combretastatin A‑4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia by Blake A. Winn (8604801)

“…The related CA1-<i>gem</i>-dimethylnitrothiophene BAPC <b>41</b> was also promising (HCR = 12.5) with complete cleavage (90 min) upon treatment with POR. In a preliminary in vivo dynamic bioluminescence imaging study, BAPC <b>45</b> (180 mg/kg, ip) induced a decrease (within 4 h) in light emission in a 4T1 syngeneic mouse breast tumor model, implying activation and vascular disruption.…”

Supplementary Material for: Alterations in Monocyte Phenotypes and Functions after a Hip Fracture in Elderly Individuals: A 6-Month Longitudinal Study by Baëhl S. (4159090)

“…An elevated expression of CX3CR1 was found only in iM. cM produced elevated quantities of TNFα. There was a transient oxidative burst of production before surgery in iM and a sustained decrease in ncM. …”

Illustration of controller breakdown of the scheme in Fig 2 when inflows to <i>A</i> exceed the outflows from <i>A</i>. by Peter Ruoff (248735)

“…<p>The setpoint of <<i>A</i>> is 2.0. Panel a: <i>A</i> (in black) and <<i>A</i>> (in blue) are shown as a function of time when <i>k</i>₁ increases successively from <i>k</i>₁=1.0 (phase 1) to <i>k</i>₁=3.0 (phase 2), and finally to <i>k</i>₁=6.0 in phase 3. …”

(A-E) The lead compound can bind to mouse Dnmt3a (PDB: 4U7P ref [18]). by Vedran Miletić (3918584)

“…(<u><b>E</b></u>) The plots show changes in pulling force and the corresponding decrease in the number of dynamic binding interactions within Dnmt3a-inhibitor complex. …”

The basic characteristics of the included studies. by Junyin Pan (20700411)

Subjects:

Common definitions and criteria for metabolic syndrome. by Junyin Pan (20700411)

Subjects:

Assessment of study bias in the included research. by Junyin Pan (20700411)

Subjects:

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. by Junyin Pan (20700411)

Subjects:

Risk of bias assessment for eligible randomized controlled trials. by Junyin Pan (20700411)

Subjects:

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. by Junyin Pan (20700411)

Subjects:

The flow chart of study selection process. by Junyin Pan (20700411)

Subjects:

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

Subjects: